It may be due to the fact that SCFAs can reduce the expression of inflammatory factors by inhibiting the activation of NF-κB, which can produce anti-inflammatory effects and interfere with precancerous cells in the early stages of CRC development. Here, NFKB1 is linked to colorectal carcinoma.